Natco Pharma launches generic of cancer drug in U.S.

Natco Pharma along with its partner Breckenridge Pharmaceutical Inc has launched Pomalidomide Capsules, a generic version of Celgene’s Pomalyst in the U.S. market.

A thalidomide analogue, the product is indicated for the treatment of multiple myeloma. It is also approved for AIDS-related Kaposi sarcoma as well as for HIV-negative adult patients with Kaposi sarcoma.

NATCO said based on information made available by the U.S. Food and Drug Administration (FDA) it believes that it has 180 days of shared exclusivity. Pomalidomide Capsules 1mg, 2mg, 3mg and 4mg had estimated sales of $3.2 billion in the U.S. for 12 months ending September 2025, the company said, citing industry sales data.

“The launch further strengthens our oncology and specialty portfolio in the U.S. We look forward to bringing more such complex and specialty products to the market in the coming years,” Natco vice chairman and CEO Rajeev Nannapaneni said in a release on Tuesday.